⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INDV News
Indivior PLC Ordinary Shares
Form 8-K
sec.gov
INDV
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
globenewswire.com
INDV
Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder
globenewswire.com
INDV
Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse
globenewswire.com
INDV
Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
globenewswire.com
INDV
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
globenewswire.com
INDV
Form 8-K
sec.gov
INDV
National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
globenewswire.com
INDV
Form 8-K
sec.gov
INDV
Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering
globenewswire.com
INDV